肿瘤细胞治疗研究
英文原题：Therapy-Related Acute Myeloid Leukemia after CAR-T Cell Therapy with Brexucabtagene Autoleucel for Mantle Cell Lymphoma.
继发性恶性肿瘤在 CAR-T 疗法后似乎更为常见。
引言：CAR-T细胞治疗用于复发/难治性（r/r）套细胞淋巴瘤后，患者生存率有所提高。随着该疗法在临床常规中的应用，CAR-T治疗后的长期事件也日益受到关注。 病例介绍：我们报告一例患者，在因r/r套细胞淋巴瘤接受brexucabtagene autoleucel（brexu-cel）CAR-T治疗26个月后，发生伴TP53双等位基因失活的急性红白血病。该患者在淋巴瘤治疗前骨髓健康。 讨论：CAR-T治疗后继发恶性肿瘤似乎更为常见。仍需开展更多研究，以评估CAR-T细胞疗法潜在的长期毒性，包括继发性髓系恶性肿瘤的发生频率。
INTRODUCTION: The introduction of CAR-T cell treatment for relapsed/refractory (r/r) mantle cell lymphoma improved survival rates of these patients. Along with its introduction in clinical routine, long-term events after CAR-T cell treatment are increasingly emerging. CASE PRESENTATION: We report the case of a patient developing acute erythroid leukemia with biallelic TP53 inactivation occurring 26 months after CAR-T therapy with brexucabtagene autoleucel (brexu-cel) for r/r mantle cell lymphoma. The patient presented with a healthy bone marrow prior to lymphoma treatments. DISCUSSION: Secondary malignancies seem more frequent after CAR-T therapies. More studies are needed to assess potential long-term toxicities of CAR-T cell therapies including the frequency of secondary myeloid malignancies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
